Drinking any amount of alcohol likely increases dementia risk: Study

Drinking any amount of alcohol likely increases the risk of dementia, suggests the largest combined observational and genetic study to date, published online in BMJ Evidence Based Medicine.

Even light drinking-generally thought to be protective, based on observational studies-is unlikely to lower the risk, which rises in tandem with the quantity of alcohol consumed, the research indicates.

Current thinking suggests that there might be an ‘optimal dose’ of alcohol for brain health, but most of these studies have focused on older people and/or didn’t differentiate between former and lifelong non-drinkers, complicating efforts to infer causality, note the researchers.

To try and circumnavigate these issues and strengthen the evidence base, the researchers drew on observational data and genetic methods (Mendelian randomisation) from two large biological databanks for the entire ‘dose’ range of alcohol consumption.

These were the US Million Veteran Program (MVP), which includes people of European, African, and Latin American ancestry, and the UK Biobank (UKB), which includes people of predominantly European ancestry.

Participants who were aged 56–72 at baseline, were monitored from recruitment until their first dementia diagnosis, death, or the date of last follow-up (December 2019 for MVP and January 2022 for UKB), whichever came first. The average monitoring period was 4 years for the US group, and 12 for the UK group.

Alcohol consumption was derived from questionnaire responses—over 90% of participants said they drank alcohol—and the Alcohol Use Disorders Identification Test (AUDIT-C) clinical screening tool. This screens for hazardous drinking patterns, including the frequency of binge drinking (6 or more drinks at a time).

In all, 559,559 participants from both groups were included in observational analyses, 14,540 of whom developed dementia of any type during the monitoring period:10,564 in the US group; and 3976 in the UK group. And 48,034 died: 28,738 in the US group and 19,296 in the UK group.

Observational analyses revealed U-shaped associations between alcohol and dementia risk: compared with light drinkers (fewer than 7 drinks a week) a 41% higher risk was observed among non-drinkers and heavy drinkers consuming 40 or more drinks a week, rising to a 51% higher risk among those who were alcohol dependent.

Mendelian randomisation genetic analyses drew on key data from multiple large individual genome-wide association studies (GWAS) of dementia, involving a total of 2.4 million participants to ascertain lifetime (rather than current) genetically predicted risks.

Mendelian randomisation leverages genetic data, minimising the impact of other potentially influential factors, to estimate causal effects: genomic risk for a trait (in this case, alcohol consumption) essentially stands in for the trait itself.

Three genetic measures related to alcohol use were used as different exposures, to study the impact on dementia risk of alcohol quantity, as well as problematic and dependent drinking.

These exposures were: self-reported weekly drinks (641 independent genetic variants); problematic ‘risky’ drinking (80 genetic variants); and alcohol dependency (66 genetic variants).

Higher genetic risk for all 3 exposure levels was associated with an increased risk of dementia, with a linear increase in dementia risk the higher the alcohol consumption.

For example, an extra 1-3 drinks a week was associated with a 15% higher risk. And a doubling in the genetic risk of alcohol dependency was associated with a 16% increase in dementia risk.

But no U-shaped association was found between alcohol intake and dementia, and no protective effects of low levels of alcohol intake were observed. Instead, dementia risk steadily increased with more genetically predicted drinking.

What’s more, those who went on to develop dementia typically drank less over time in the years preceding their diagnosis, suggesting that reverse causation-whereby early cognitive decline leads to reduced alcohol consumption-underlies the supposed protective effects of alcohol found in previous observational studies, say the researchers.

They acknowledge that a principal limitation of their findings is that the strongest statistical associations were found in people of European ancestry, because of the numbers of participants of this ethnic heritage studied. Mendelian randomisation also relies on assumptions that can’t be verified, they add.

Nevertheless, they suggest that their findings “challenge the notion that low levels of alcohol are neuroprotective.”

And they conclude: “Our study findings support a detrimental effect of all types of alcohol consumption on dementia risk, with no evidence supporting the previously suggested protective effect of moderate drinking.

“The pattern of reduced alcohol use before dementia diagnosis observed in our study underscores the complexity of inferring causality from observational data, especially in ageing populations.

“Our findings highlight the importance of considering reverse causation and residual confounding in studies of alcohol and dementia, and they suggest that reducing alcohol consumption may be an important strategy for dementia prevention.”

Reference:

Topiwala, A., et al. (2025) Alcohol use and risk of dementia in diverse populations: evidence from cohort, case-control and Mendelian randomisation approaches. BMJ Evidence Based Medicine. DOI: 10.1136/bmjebm2025-113913

Powered by WPeMatico

Methylphenidate Safe but Ineffective for Cancer-Related Fatigue: Study

UK: Researchers have found in a new study that methylphenidate did not significantly reduce fatigue severity in patients with advanced cancer after 6 (± 2) weeks of treatment. However, it was found to be safe and well-tolerated.

The phase III, double-blind, placebo-controlled trial, published in Health Technology Assessment and led by Dr. Patrick Stone and colleagues from the Marie Curie Palliative Care Research Department, University College London, aimed to assess whether methylphenidate could offer clinical benefit for cancer-related fatigue in palliative care patients. This large-scale study involved 162 adults with advanced cancer and moderate-to-severe fatigue, recruited from 17 palliative care services across England between June 2018 and April 2023.

Patients were randomly assigned to receive either methylphenidate or a placebo, with the medication dose gradually increased over six weeks, depending on individual response and side effects. The primary objective was to evaluate changes in fatigue levels after six weeks, using the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) scale.

The following were the key findings of the study:

  • Patients receiving methylphenidate showed slightly better fatigue scores compared to the placebo group, but the difference was neither statistically nor clinically significant.
  • At six weeks, the mean fatigue score improvement in the methylphenidate group was 1.97 points higher, which did not meet the 5-point threshold for clinical significance.
  • Over the full study period, the average improvement in fatigue was nominally significant (Diff 2.20), yet still fell short of clinical relevance.
  • Secondary outcomes, such as quality of life, physical symptoms, and activities of daily living, showed no significant differences between the two groups.
  • A small but statistically significant reduction in depression scores was observed in the methylphenidate group.
  • Serious adverse events were reported at similar rates in both groups, with no unexpected reactions.
  • There was no increased risk of death among participants receiving methylphenidate.

Despite previous meta-analyses suggesting that methylphenidate may benefit cancer-related fatigue, this rigorous trial did not confirm a meaningful therapeutic effect. Researchers highlighted the highly selective nature of the participant group due to extensive exclusion criteria and noted that the chosen threshold for clinical significance may be open to debate.

Given the findings, the authors concluded that methylphenidate should not be recommended for managing fatigue in patients with advanced cancer receiving palliative care. However, they acknowledged the potential for further research into its use in other populations or for different indications.

“Cancer-related fatigue remains a challenging symptom to treat, and while methylphenidate was shown to be safe, its effectiveness in this context appears limited based on current evidence,” they wrote.

Reference:

Stone P, Minton O, Richardson A, Buckle P, Enayat ZE, Marston L, Freemantle N. Methylphenidate versus placebo for fatigue in patients with advanced cancer: the MePFAC randomised controlled trial. Health Technol Assess 2025;29(36). https://doi.org/10.3310/GJPS6321

Powered by WPeMatico

Graves’ Disease Linked to Higher Risk of Psychiatric Disorders: Study

Researchers have found in a new nationwide population-based study published in the Journal of Affective Disorders that patients with Graves’ disease face a significantly higher risk of developing psychiatric disorders compared with the general population, highlighting the complex interplay between thyroid autoimmunity, neuropsychiatric health, and long-term disease management. The study analyzed a large cohort of individuals diagnosed with Graves’ disease against matched controls and found that the risk was particularly elevated for depression, bipolar disorder, anxiety disorders, and sleep disturbances, with these associations persisting even two years after the initial diagnosis. Interestingly, no significant association was observed between Graves’ disease and the risk of schizophrenia, suggesting that the thyroid-psychiatric link may be specific to certain mental health conditions rather than encompassing all psychiatric disorders. These findings underscore the importance of integrating psychological assessment and monitoring into routine clinical care for patients with Graves’ disease, as mental health complications may extend beyond the acute phase of endocrine dysfunction and persist well into long-term follow-up. The mechanisms underlying these associations may involve immune-mediated pathways, alterations in thyroid hormone regulation affecting neurotransmitter systems, chronic disease burden, or psychosocial stressors related to living with a long-term autoimmune condition. For clinicians, the results reinforce the need for interdisciplinary collaboration between endocrinologists, psychiatrists, and primary care physicians to ensure early detection and appropriate management of psychiatric symptoms in patients with Graves’ disease. For patients, the findings highlight the importance of awareness regarding mood changes, anxiety, or sleep disturbances as possible complications linked to their thyroid condition, emphasizing the role of proactive mental health care in improving quality of life and treatment outcomes. While the study provides robust evidence from a large dataset, further research is warranted to explore causal mechanisms, evaluate the impact of antithyroid treatments on psychiatric risk, and determine whether early psychological interventions can mitigate long-term complications. Overall, the study strengthens the argument for holistic management approaches that address both the endocrine and psychological dimensions of Graves’ disease.

Keywords: Graves’ disease, psychiatric disorders, depression, bipolar disorder, anxiety, sleep disorder, thyroid autoimmunity, Journal of Affective Disorders

Reference: Journal of Affective Disorders. “Risk of psychiatric disorders in patients with Graves’ disease: A nationwide population-based analysis.” Published September 16, 2025. DOI: 10.1016/j.jad.2025.09.041.

Powered by WPeMatico

Taking semaglutide turns down food noise, research suggests

Food noise refers to obsessive and intrusive thoughts about food and eating. This preoccupation with food can hinder healthy lifestyle implementation and lead to overeating, making weight loss difficult.

Previous research has found that 57% of people who have living with overweight or obesity have experienced food noise, although few are familiar with the term. Many of those affected said that food noise made it more difficult to make healthy food choices or stick to an exercise plan.1

Some people also report that food noise affects their quality of life and their wellbeing.2

Glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (brand names Wegovy and Ozempic) are highly effective at helping people who are living with obesity lose weight. By mimicking the action of a hormone called GLP-1, they reduce appetite and feelings of hunger, slow the release of food from the stomach and increase feelings of fullness after eating.

However, little is known about how semaglutide, which was developed by Danish pharmaceutical company Novo Nordisk A/S, affects food noise.

To find out more, researchers from Novo Nordisk and Market Track LLC, a market research company, conducted a survey of 550 people in the US (average age 53 years, 86% female) who were taking semaglutide for weight loss.

Some 81% (447) of the participants said they had been taking semaglutide for at least four months and 86% of the participants reported weighing at least 92kg (14st 7lb) before starting treatment.

The participants were asked how food noise was currently affecting them and to recall how it had affected them before starting treatment.

Analysis of the results showed that the participants were experiencing less food noise than before.

The proportion of participants experiencing constant thoughts about food throughout the day fell almost four-fold from 62% before starting treatment to 16%. The proportion who said they spent too much time thinking about food fell by a similar amount, from 63% to 15%.

The proportion who said they had uncontrollable thoughts about food fell more than three-fold from 53% to 15%; the proportion who said their thoughts about food had negative effects on them or their life fell from 60% to 20%; and the proportion who said their thoughts about food distracted them from completing everyday activities fell from 47% to 15%.

The survey also contained questions that covered several areas of mental wellbeing.

Here, 352 (64%), 417 (76%) and 438 (80%) of the respondents reported an improvement in mental health, self-confidence and the development of healthier habits, respectively.

It is not known if these improvements were related to the drop in food noise or to the participants’ weight loss.

The study’s authors conclude that semaglutide may reduce the amount of food noise that is experienced by individuals who are living with obesity.

Reference: Taking semaglutide turns down food noise, research suggests, Annual Meeting of the European Association for the Study of Diabetes (EASD)

Powered by WPeMatico

Delivery Dilemmas: Study evaluating Obesity’s Influence on Cesarean Section Trends

Recent study investigated the relationship between second-trimester anthropometric obesity indicators and cesarean section (CS) in Chinese pregnant women, aiming to identify effective predictors to reduce unnecessary CS rates. The research highlighted the increasing global CS rates and the associated short- and long-term risks for both mothers and infants. Maternal obesity during the second trimester has been linked to an elevated CS risk, emphasizing the need for reliable obesity indicators for prenatal risk assessment. Different indicators like Body Mass Index (BMI), Subcutaneous Fat Thickness (SCFT), Waist Circumference (WC), Body Fat Percentage (BFP), and Body Roundness Index (BRI) were evaluated for their associations with CS risk.

Key Findings and Associations

The findings showed that BMI, BFP, WC, and BRI were significant predictors of CS risk, with BRI demonstrating the strongest association. Maternal age and fetal sex were identified as modifiers influencing these associations, with advanced maternal age and male infants showing heightened CS risks. The study included a large sample of Chinese pregnant women, and statistical analyses revealed significant correlations between anthropometric indicators and CS risk after adjusting for covariates.

Recommendations for CS Risk Assessment

Integrated approaches combining BMI and WC were recommended for effective CS risk assessment, with BRI being a superior indicator despite its complexity. The study emphasized the importance of early identification of high-risk subgroups and integrating obesity-related indicators into routine prenatal care to optimize delivery planning and develop targeted interventions. The research findings suggested that an individualized perinatal care approach using multiple anthropometric indicators could enhance risk stratification and improve maternal and neonatal outcomes.

Limitations and Future Research Directions

While the study provided valuable insights into the associations between anthropometric obesity indicators and CS risk, certain limitations such as the observational design, single-center setting, limited participant characteristics, and the need for further longitudinal studies to confirm the findings were acknowledged. Future research directions were proposed to explore the longitudinal impact of maternal adiposity changes on delivery outcomes and develop accessible tools for integrating anthropometric indicators into routine obstetric care for enhanced risk assessment and improved maternal health outcomes.

Key Points

– Investigated the relationship between second-trimester anthropometric obesity indicators and cesarean section (CS) in Chinese pregnant women to identify predictors for reducing unnecessary CS rates in response to the increasing global CS rates and associated risks for mothers and infants.

– Found that Body Mass Index (BMI), Body Fat Percentage (BFP), Waist Circumference (WC), and Body Roundness Index (BRI) were significant predictors of CS risk, with BRI showing the strongest association, while maternal age and fetal sex modulated these associations.

– Recommended integrated BMI and WC approaches for effective CS risk assessment, suggesting the superiority of BRI as an indicator and highlighting the importance of early identification of high-risk subgroups and integrating obesity-related indicators into routine prenatal care.

– Acknowledged study limitations such as observational design, single-center setting, and the need for further longitudinal research to confirm findings, proposing future directions to explore the impact of maternal adiposity changes on delivery outcomes and develop accessible tools for enhanced risk assessment in obstetric care.

– Emphasized the need for reliable obesity indicators for prenatal risk assessment due to the linkage between maternal obesity during the second trimester and elevated CS risk, aiming to optimize delivery planning, develop targeted interventions, and improve maternal and neonatal outcomes through individualized perinatal care approaches using multiple anthropometric indicators.

Reference –

Anqi Xiong et al. (2025). Second-Trimester Anthropometric Estimators Of Cesarean Section: The Agreement Between Body Roundness Index, Body Mass Index, Body Fat Percentage, And Waist Circumference. *BMC Pregnancy And Childbirth*, 25. https://doi.org/10.1186/s12884-025-07643-8.

Powered by WPeMatico

Ferritin-to-Albumin Ratio Predicts Mortality Risk in Non-COVID-19 Pneumonia Patients: Study

A new study has found that the ferritin-to-albumin ratio (FAR), a biomarker that reflects both inflammation and nutritional status, can predict short-term mortality in critically ill patients with non-COVID-19 pneumonia. The findings highlight how routinely available blood tests may offer valuable insights into patient outcomes, providing a practical way to identify those at higher risk.

The research, published in Respiratory Medicine (Feng et al., 2025), analyzed data from 827 patients admitted with pneumonia to the intensive care unit. By examining ferritin, a marker of systemic inflammation, alongside albumin, which reflects nutritional and physiological reserve, the team calculated each patient’s FAR and tracked survival over 28 and 90 days. Patients with higher ratios at admission consistently showed a greater risk of death during both time frames. This association remained significant even after adjusting for demographics, comorbidities, and other clinical variables. The results suggest that FAR captures the combined impact of inflammation and nutritional depletion on patient outcomes, offering a more holistic measure than single biomarkers alone.

The study’s authors emphasize the potential for FAR to be used as a simple, cost-effective tool in critical care settings. Because ferritin and albumin levels are already part of standard laboratory testing, clinicians could easily calculate FAR without requiring additional procedures or expenses. This could aid in early risk stratification, helping identify patients who may need closer monitoring or more aggressive treatment. Although further prospective studies are needed to validate the findings, the evidence suggests that FAR could complement existing severity scores and guide personalized care strategies for patients with pneumonia. By bridging inflammation and nutrition into a single measure, FAR may become a valuable addition to the clinician’s toolkit for improving outcomes in serious respiratory infections.

Reference: Feng, J., Zhao, T., Huang, Y., Lai, S., & Chen, G. (2025). Ferritin-to-Albumin Ratio Predicts Short-Term Mortality in Critically Ill Patients with Non-COVID-19 Pneumonia: A Retrospective Cohort Study from MIMIC-IV database. Respiratory Medicine. https://doi.org/10.1016/j.rmed.2025.108361

Keywords: ferritin-to-albumin ratio, non-COVID-19 pneumonia, inflammation, nutrition, mortality risk, intensive care, prognostic biomarker.

Powered by WPeMatico

Allahabad HC Flags Procedural Flaws, Quashes Drugs Case Summons Against Pharma Firm

New Delhi: The Allahabad High Court has quashed the summoning order issued against Associated Biotech and its directors in a drugs (Amoxycillin) quality case, holding that the trial court failed to comply with statutory safeguards and passed a “cryptic and unreasoned” order.

The judgment was delivered by Justice Vikas Budhwar, who examined whether the Special Judge (Drugs and Cosmetics), Aligarh, had adhered to the requirements of the Drugs and Cosmetics Act and the Bharatiya Nagarik Suraksha Sanhita (BNSS), 2023, while summoning the accused.

The case stemmed from an inspection carried out at Vimla Medical Store, Aligarh on August 23, 2023. A sample of Amoxycillin was drawn and later tested by the Government Analyst, Lucknow, who reported on October 13, 2023, that the drug did not conform to standards of the Indian Pharmacopoeia. Subsequent inquiry revealed that the medicines had been supplied through M/s Somkee India Pvt. Ltd., which had procured them from M/s Associated Biotech. A complaint was filed on September 23, 2024, and on November 15, 2024, the Special Judge summoned the company and its directors under Sections 18 and 27 of the Drugs and Cosmetics Act.

Challenging the summoning order, the applicants contended that:

  • The order was non-speaking, unreasoned, and failed to even record the complainant’s case.
  • Their statutory right under Section 25 of the Drugs and Cosmetics Act to seek retesting from a central laboratory was denied.
  • The Sessions Court lacked jurisdiction to summon them without a committal order from the Magistrate under Section 193 CrPC/213 BNSS.
  • Since the complaint was filed after BNSS-2023 came into force, they were entitled to be heard at the pre-cognizance stage under Section 223(1) BNSS.

The Additional Government Advocate, Sri Pankaj Srivastava, argued that prima facie offenses were indeed disclosed from the complaint. However, he conceded that the summoning order did not pass the test of legality as laid down by the Supreme Court and therefore should be set aside and the matter remitted back for fresh consideration.

The High Court found that the summoning order of November 15, 2024:

  • Did not mention whether the accused had been given a chance to be heard as required under Section 223(1) BNSS.
  • Was cryptic, lacking reasons, and failed to reflect even the basic case of the complainant.
  • Violated the standards set by the Supreme Court in JM Laboratories v. State of Andhra Pradesh (2025 INSC 127) and other rulings, which require speaking and reasoned orders while issuing summons.

Final Ruling:

Quashing the order, Justice Budhwar ruled;

“The order dated 15.11.2024 passed in Complaint Case No. 3654 of 2024 summoning the applicants under Section 18 and 27 of the Drugs and Cosmetics Act passed by learned Additional Sessions Judge, VIII, Aligarh is set aside; the matter stands remitted back to the court below to pass a fresh order.”

To view the official judgement, click the link below:

Powered by WPeMatico

Laser correction for short-sightedness is safe and effective for older teenagers: Study

Denmark: A major study of laser correction for short-sightedness shows that the procedure is as safe and effective in older teenagers as it is in adults, according to research presented today (Tuesday) at the 43rd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS).

Short-sightedness, or myopia, affects around a third of children and teenagers and research suggests that it is becoming more common.

A laser treatment, called photorefractive keratectomy (PRK), is widely used to treat myopia in adults but questions remain over its use in teenagers.

The new study was presented by Dr Avinoam Shye, from the Department of Ophthalmology at Rambam Health Care Campus in Haifa, Israel. He said: “Some doctors worry that the eyes of teenagers may still be changing or that their eyes might respond differently to healing after laser treatment, increasing the risk of side effects. However, in certain situations teenagers do want permanent solutions to their myopia.

“We noticed that despite these concerns, many teenagers aged 17 or 18 were getting excellent results. That led us to study whether PRK is truly a safe and effective option for this age group.”

The study included a group of patients with myopia who were treated with PRK at Care-Vision Laser Centers, Tel Aviv, Israel, between January 2010 and June 2024, with 65,211 eyes treated in total.

PRK involves using a laser to remove tissue from the cornea, the clear, dome-shaped layer that covers the pupil and iris. The cornea acts as window for light to enter the eye, so reshaping the cornea can improve the way light enters the eye and treat vision problems including myopia.

Dr Shye and his colleagues grouped the patients according to their age, so they could compare the effects of laser treatment in those aged 17 to 18 with those aged 19 to 40.

They found that the outcomes for older teenagers were as good or even better than they were for adults. Around 64% of the teenagers’ eyes achieved 20/20 vision (normal visual acuity), compared with 59% of adult eyes.

The proportion of eyes that required a second treatment was very low (0.41%) in both groups. Complications such as hazy vision or weakening of the cornea (ectasia) were also very rare in both groups.

Dr Shye said: “This is by far the largest study of PRK in teenagers, and this large sample size means the findings are very reliable. A limitation is that it is a retrospective study, meaning we analysed data that were already collected, rather than setting up a new trial from the beginning.

“The research suggests that for well-screened teenagers with stable myopia, PRK could be a safe and effective option, especially when contact lenses or glasses are not ideal. These findings may support expanding the criteria for offering PRK to selected teenagers. Age alone should not disqualify a motivated and well-suited teenager from having this treatment.”

The researchers will continue to monitor the teenagers who received laser treatment to check for very late complications or changes in vision.

Professor Thomas Kohnen is Chair of the ESCRS Publication Committee, Director of the Department of Ophthalmology at Goethe University Frankfurt, Germany, and was not involved in the research. He said: “Short sightedness is increasing worldwide in children and teenagers, and it can worsen up to the age of 30. In children, short sightedness is treated with glasses or contact lenses, while adults can choose to have laser treatment to correct their vision.

“This large cohort study of photorefractive keratectomy for treating short sightedness shows that the procedure is safe and effective for older teenagers, suggesting that this could be an alternative option to glasses or contact lenses for some young people.”

Powered by WPeMatico

Negligence during surgery, missing notes: NCDRC slams hospital, orders Rs 5 lakh compensation

New Delhi: The National Consumer Disputes Redressal Commission (NCDRC) recently upheld the charges of medical negligence against a Karnataka-based hospital, which was told to pay Rs 5 lakh compensation to a patient.

Previously, while considering the matter, the District Commission had held the neurosurgeon negligent and directed him to pay Rs 15 lakh compensation to the patient, whereas the hospital had been slapped with Rs 5 lakh compensation.

While considering the hospital’s appeal against the district and state consumer court verdicts, the Apex Consumer Court opined that the District Commission order was fully justified in holding the hospital negligent. NCDRC observed that the discharge summary was incomplete, and operation notes were not provided despite an RTI appeal. 

The history of the case goes back to 2007, when a spinal surgery on the patient was performed at the treating hospital by a neurosurgeon. While performing the surgery, a metallic screw was utilised, and a minute fragment of the said screw seemed to have scraped during the performance of the surgery, which got lodged somewhere around the area of surgery.

Later, the patient discovered that such a metallic object was left behind when he faced some complications. After inquiring into the matter and obtaining some details, he filed a consumer complaint before the Dakshina Kannada District Consumer Disputes Redressal Commission, Mangalore, Karnataka.

The District Commission, through an elaborate order dated 29.10.2010, held the surgeon liable for negligence on a clear finding that the piece of metal that was left behind during the process of surgery was an act of gross negligence. Accordingly, the District Consumer Court allowed the complaint and directed the surgeon to pay Rs 15 lakh with interest @ 9% from the date of the complaint till the date of payment.

Further, the District Commission also held the petitioner hospital liable for not informing the patient/complainant about the said lapse in the procedure. Apart from this, the Commission held that the hospital had issued a discharge summary cryptically without mentioning the aforesaid lapse, which stood admitted in view of the evidence on record and the admissions made by the doctors themselves.

It was also held that the operation notes had not been provided and the complainant had to file applications under the Right to Information Act and it was much later when the complainant went to his work in Dubai, he experienced pain, whereafter he got himself examined and the radiological reports confirmed the lodging of the splinter metal in his body that was deliberately not informed by the hospital. Accordingly, the hospital was also held liable and was directed to pay a sum of Rs 5.00 Lakhs together with interest.

The hospital and the neurosurgeon challenged the District Commission’s order before the Karnataka State Consumer Court, which upheld the District Commission’s order and dismissed the appeals.

Consequently, the treating hospital filed a revision petition before the NCDRC bench. The counsel for the hospital argued that the hospital was a charitable institution and, therefore, was not liable for any deficiency. It was also submitted that the District Commission had already recorded a finding that even the surgical instruments that were utilised by the doctor during the surgery were not supplied by the hospital and belonged to the doctor alone. Therefore, any negligence by the doctor while performing the surgery could not be saddled as a deficiency against the hospital, argued the top consumer court.

Further, the counsel submitted that all documents had been provided to the complainant, and in fact, there was no evidence to draw any inference of deficiency against the hospital. 

However, the counsel for the complainant urged that the deficiency regarding non-supply of the documents, providing a deficit discharge summary without mentioning the negligence of the doctors, was a deficiency in service.

After going through the District Commission’s orders, as well as the findings recorded by it, the Commission observed that the information regarding the presence of a metallic object that was left behind during surgery was not mentioned in the discharge summary that was admittedly issued by the petitioner hospital.

At this outset, the Commission observed,

“The discharge summary is cryptic and without any indication of the fact of the presence of the metallic object which stood admitted and was left inside the body of the patient. The hospital had the custody of the operation notes and there can be no two opinion that the said notes did indicate the presence of a cut-piece surgical instrument inside the body. Not only this, the patient had been taken inside the operation theatre for the second time and it was the evidence of the doctor before the District Commission that he had informed the complainant/respondent no.1 (patient) about the presence of the metal inside the body immediately after the operation with an assurance that it will not have any side effect. It is therefore evident that the fact of the presence of the metallic object stood admitted by the surgeon being present in the body of the complainant/respondent no.1 and its mention in the operation notes which were in the custody of the petitioner/hospital. The petitioner hospital has been unable to give any explanation as to why the said fact was omitted from being mentioned in the discharge summary of the hospital.”

Opining that the District Commission’s order was justified, the Apex Consumer Court held,

“In our opinion, the District Commission was fully justified in drawing an adverse inference against the petitioner hospital on that count. The negligence of the petitioner hospital in providing a discharge summary which was clearly incomplete and which withheld a material fact affecting the health of the complainant/respondent no.1 was therefore a gross negligence. Not only this, the operation notes were also provided after an attempt was made under the Right to Information Act. This also, in our opinion, was a deficiency on which the District Commission has rightly arrived at a correct conclusion. The findings of the District Commission have been therefore appropriately confirmed in appeals and these findings of fact do not suffer from any perversity or non-consideration of relevant material.”

With this observation, the NCDRC dismissed the review petition.

To view the order, click on the link below:

https://medicaldialogues.in/pdf_upload/ncdrc-upholds-compensation-301953.pdf

Also Read: Nerve injury due to negligence in spinal anaesthesia: Consumer court slaps Rs 3.2 lakh compensation on hospital, doctors

Powered by WPeMatico

Lactate IV infusion found to trick the body into releasing a hormone behind that post-workout brain boost

Science has confirmed what sports lovers have always known from experience: exercise is good for the brain. It increases blood flow, inhibits stress hormones, and stimulates the release of ‘feel good’ endorphins. One way by which exercise is thought to yield these benefits on the brain is through a chain of processes that ultimately results in the release of the hormone BDNF. Produced by the liver, brain, skeletal muscle, and fat tissue, BDNF is known to promote the growth, survival, and maintenance of nerve cells.

Powered by WPeMatico